Johnson & Johnson (JNJ) Receivables - Net (2009 - 2026)
Johnson & Johnson (JNJ) posted Receivables - Net of $17.7 billion for Q1 2026, up 3.16% sequentially from $17.2 billion in Q4 2025, and up 10.62% YoY from $16.0 billion in Q1 2025.
Johnson & Johnson (JNJ) Receivables - Net (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Receivables - Net data on file, last reported at $17.7 billion in Q1 2026.
- Quarterly Receivables - Net rose 10.62% year-over-year to $17.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 billion (up 10.62% YoY) and the FY2025 annual result came in at $17.2 billion, up 15.74% from the prior year.
- Receivables - Net grew to $17.7 billion in Q1 2026 per JNJ's latest filing, from $17.2 billion in the prior quarter.
- The five-year high for Receivables - Net was $17.8 billion in Q2 2025, with the low at $14.0 billion in Q1 2023.
- Average Receivables - Net over 5 years is $16.0 billion, with a median of $16.0 billion recorded in 2022.
- Year-over-year, Receivables - Net declined 8.59% in 2024 and rose 15.74% in 2025.
- Johnson & Johnson's Receivables - Net stood at $15.9 billion in 2022, then declined by 6.4% to $14.9 billion in 2023, then slipped by 0.21% to $14.8 billion in 2024, then gained by 15.74% to $17.2 billion in 2025, then grew by 3.16% to $17.7 billion in 2026.
- Business Quant data shows JNJ's Receivables - Net at $17.7 billion in Q1 2026, $17.2 billion in Q4 2025, and $17.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 17.72 Bn |
| Mar 29, 2026 | 17.72 Bn |
| Dec 28, 2025 | 17.18 Bn |
| Dec 28, 2025 | 17.18 Bn |
| Sep 28, 2025 | 17.61 Bn |
| Sep 28, 2025 | 17.61 Bn |
| Jun 29, 2025 | 17.85 Bn |
| Jun 29, 2025 | 17.85 Bn |
| Mar 30, 2025 | 16.02 Bn |
| Mar 30, 2025 | 16.02 Bn |
| Dec 29, 2024 | 14.84 Bn |
| Dec 29, 2024 | 14.84 Bn |
| Sep 29, 2024 | 16.17 Bn |
| Sep 29, 2024 | 16.17 Bn |
| Jun 30, 2024 | 15.79 Bn |
| Jun 30, 2024 | 15.79 Bn |
| Mar 31, 2024 | 14.95 Bn |
| Mar 31, 2024 | 14.95 Bn |
| Dec 31, 2023 | 14.87 Bn |
| Dec 31, 2023 | 14.87 Bn |